Telix Pharma signs deals with two European pharma companies

Australia’s Telix Pharmaceuticals had a busy day, announcing a product development partnership with German company Therapeia as well as a collaboration with Atlab Pharma of France.

Telix will add Therapeia’s ACD-101 theranostic program for glioblastoma to its pipeline of advanced theranostic radiopharmaceutical products. Telix also has secured the option to acquire Therapeia under pre-agreed terms. The financial terms of the transaction are not disclosed.

Telix chief executive Chris Behrenbruch stated: “ACD-101 is a unique multi-action agent that has the potential to deliver something really new to the management of several very challenging malignancies, particularly glioblastoma. Early patient experience in Germany has demonstrated promising therapeutic results and we are excited to be working with the Therapeia team to take this program forward to Phase II and beyond.”